CSL Behring
Biotherapies for Life™

# CSL Research Acceleration Initiative

## Applications close 12th March 2021

### WHY COLLABORATE WITH CSL?

**Global** Capabilities on your doorstep

**Work** with one of the world's leading biotech companies

**Funding** for successful proposals

**Access** to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise

**Accelerate** translation of your research to deliver new therapies to patients

CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations.

The 2021 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.




Successful applicants will receive up to USD 200k p.a. for up to 2 years (max USD 400k funding).

Researchers who wish to apply are required to submit a 300 word online pre-application by **12th March 2021** via the following link https://servicesplatform.partneringplace.com/OppPortal/portal/csl/.
Shortlisted applicants will then be invited to submit a detailed proposal in April.

Interested researchers are invited to join an online information session to learn more. Times and links will be announced separately by your Research or Innovation Office.
*Please note: only Researchers from registered Institutions are eligible to apply*

# CSL Research Acceleration Initiative

## Focus Areas

CSL is seeking applications in the following **Focus Areas**:




**Focus Areas**

**Autoimmune diseases**
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms of: Sjögren's syndrome, Systemic sclerosis, SLE, Pemphigus vulgaris, Hidradenitis suppurativa, Dermatomyositis, other rare rheumatological/ dermatological conditions

**Inflammation**
Novel strategies to modulate the immune system to treat inflammatory diseases (including neuroinflammation e.g. CIDP)

**Next generation IVIG / alternatives to plasma-derived IVIG**

**Sickle cell disease**
Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy

**Ischemic and hemorrhagic stroke**
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms

Focus on neuro- and thrombo-inflammation/ novel thrombolytics

Biomarker/Omics approaches for patient stratification and drug discovery

**Hemophilia**
*In vivo* gene-editing and technologies for liver targeted delivery

**Interstitial lung diseases** (progressive, fibrosing)
Novel biologic targets/ therapeutics

Biomarker/Omics approaches for patient stratification and drug discovery

Novel animal and human disease models

**Acute respiratory distress syndrome**
Novel biologic targets/ therapeutics

Biomarker/Omics approaches for patient stratification and drug discovery

**Alpha-1 antitrypsin deficiency**
In vivo gene-editing and technologies for liver targeted delivery

**Rare lipid disorders** (e.g. Familial hypercholesterol-emia, Familial chylomicronemia)
In vivo gene-editing and technologies for liver targeted delivery

**Severe forms of atherosclerosis**
Novel biologic targets/ therapeutics or strategies to understand pathomechanisms

**Refractory angina**
Novel biologic targets/ therapeutics

**Myocarditis**
Novel biologic targets/ therapeutics

Novel animal and human disease models

Access to patient samples

**Tolerance** (Solid organ transplant/HSCT)
Novel strategies or biologics to induce tolerance (T regs, T cell anergy and/or tolerogenic DCs)

**Graft vs host disease**
Novel biologic targets/ therapeutics to modulate the immune response for treatment and prevention

**Acute rejection** (Antibody-mediated rejection)
Novel biologic targets/ therapeutics to modulate the immune response

**Hematopoietic stem cell transplants**
Strategies to improve efficacy/ safety, including inducing stem cell mobilisation, reducing toxicity of BM conditioning, improvement of engraftment

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.